-
1
-
-
27544465823
-
Mesothelioma
-
In: Travis WD, Brambilla E, Muller-Hermelink HK et al (eds), IARC press, Lyon
-
Churg A, Roggli V, Galateau-Salle F et al (2004) Mesothelioma. In: Travis WD, Brambilla E, Muller-Hermelink HK et al (eds) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC press, Lyon, pp 128-136
-
(2004)
Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart
, pp. 128-136
-
-
Churg, A.1
Roggli, V.2
Galateau-Salle, F.3
-
2
-
-
46349091630
-
Current concepts in chemotherapy for malignant pleural mesothelioma
-
Sorensen JB (2008) Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 2:74-79
-
(2008)
Clin Respir J
, vol.2
, pp. 74-79
-
-
Sorensen, J.B.1
-
4
-
-
79851511500
-
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
-
Gridelli C, De MF, Di MM et al (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer 71:249-257
-
(2011)
Lung Cancer
, vol.71
, pp. 249-257
-
-
Gridelli, C.1
De, M.F.2
Di, M.M.3
-
5
-
-
0024337144
-
Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
6
-
-
20044364933
-
Egfr mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
-
Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865
-
(2005)
J Clin Oncol
, vol.23
, pp. 857-865
-
-
Marchetti, A.1
Martella, C.2
Felicioni, L.3
-
7
-
-
0345256652
-
Cisplatin: Mode of cytotoxic action and molecular basis of resistance
-
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
-
(2003)
Oncogene
, vol.22
, pp. 7265-7279
-
-
Siddik, Z.H.1
-
9
-
-
77956124352
-
Ercc1 and histopathology in advanced nsclc patients randomized in a large multicenter phase iii trial
-
Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21:1817-1824
-
(2010)
Ann Oncol
, vol.21
, pp. 1817-1824
-
-
Vilmar, A.C.1
Santoni-Rugiu, E.2
Sorensen, J.B.3
-
10
-
-
33748435058
-
Dna repair by ercc1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
-
Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991
-
(2006)
N Engl J Med
, vol.355
, pp. 983-991
-
-
Olaussen, K.A.1
Dunant, A.2
Fouret, P.3
-
11
-
-
69449090272
-
The relationship of platinum resistance and ercc1 protein expression in epithelial ovarian cancer
-
Steffensen KD, Waldstrom M, Jakobsen A (2009) The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19:820-825
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 820-825
-
-
Steffensen, K.D.1
Waldstrom, M.2
Jakobsen, A.3
-
12
-
-
78649497050
-
Excision repair crosscomplementation group 1 (ercc1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
-
Kim KH, Do IG, Kim HS et al (2010) Excision repair crosscomplementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 118:941-948
-
(2010)
APMIS
, vol.118
, pp. 941-948
-
-
Kim, K.H.1
Do, I.G.2
Kim, H.S.3
-
13
-
-
9744263911
-
The role of brca1 in the cellular response to chemotherapy
-
Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 1659-1668
-
-
Kennedy, R.D.1
Quinn, J.E.2
Mullan, P.B.3
-
14
-
-
0037403380
-
Improved survival in women with brca-Associated ovarian carcinoma
-
Cass I, Baldwin RL, Varkey T et al (2003) Improved survival in women with BRCA-Associated ovarian carcinoma. Cancer 97:2187-2195
-
(2003)
Cancer
, vol.97
, pp. 2187-2195
-
-
Cass, I.1
Baldwin, R.L.2
Varkey, T.3
-
15
-
-
19544379515
-
Brca1 mrna expression levels as an indicator of chemoresistance in lung cancer
-
Taron M, Rosell R, Felip E et al (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449
-
(2004)
Hum Mol Genet
, vol.13
, pp. 2443-2449
-
-
Taron, M.1
Rosell, R.2
Felip, E.3
-
16
-
-
21444446876
-
Differential sensitivity of brca1-mutated hcc1937 human breast cancer cells to microtubule-interfering agents
-
Tassone P, Blotta S, Palmieri C et al (2005) Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 26:1257-1263
-
(2005)
Int J Oncol
, vol.26
, pp. 1257-1263
-
-
Tassone, P.1
Blotta, S.2
Palmieri, C.3
-
17
-
-
65649146783
-
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of brca1
-
Stordal B, Davey R (2009) A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 9:354-365
-
(2009)
Curr Cancer Drug Targets
, vol.9
, pp. 354-365
-
-
Stordal, B.1
Davey, R.2
-
18
-
-
0141954010
-
Brca1 functions as a differential modulator of chemotherapy-induced apoptosis
-
Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221-6228
-
(2003)
Cancer Res
, vol.63
, pp. 6221-6228
-
-
Quinn, J.E.1
Kennedy, R.D.2
Mullan, P.B.3
-
19
-
-
33847304077
-
Brca1-A good predictive marker of drug sensitivity in breast cancer treatment
-
Mullan PB, Gorski JJ, Harkin DP (2006) BRCA1-A good predictive marker of drug sensitivity in breast cancer treatment Biochim Biophys Acta 1766:205-216
-
(2006)
Biochim Biophys Acta
, vol.1766
, pp. 205-216
-
-
Mullan, P.B.1
Gorski, J.J.2
Harkin, D.P.3
-
20
-
-
77649191871
-
Microtubules and resistance to tubulinbinding agents
-
Kavallaris M (2010) Microtubules and resistance to tubulinbinding agents. Nat Rev Cancer 10:194-204
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 194-204
-
-
Kavallaris, M.1
-
21
-
-
35148854099
-
Class iii beta-Tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer
-
Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-Tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67:9356-9363
-
(2007)
Cancer Res
, vol.67
, pp. 9356-9363
-
-
Gan, P.P.1
Pasquier, E.2
Kavallaris, M.3
-
22
-
-
38549161093
-
Is class iii beta-Tubulin a predictive factor in patients receiving tubulin-binding agents
-
Seve P, Dumontet C (2008) Is class III beta-Tubulin a predictive factor in patients receiving tubulin-binding agents Lancet Oncol 9:168-175
-
(2008)
Lancet Oncol
, vol.9
, pp. 168-175
-
-
Seve, P.1
Dumontet, C.2
-
23
-
-
23044435044
-
Expression of class iii {beta}-Tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
-
Seve P, Isaac S, Tredan O et al (2005) Expression of class III {beta}-Tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-5486
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5481-5486
-
-
Seve, P.1
Isaac, S.2
Tredan, O.3
-
24
-
-
30344437279
-
Class iii beta-Tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
-
Seve P, Mackey J, Isaac S et al (2005) Class III beta-Tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 2001-2007
-
-
Seve, P.1
Mackey, J.2
Isaac, S.3
-
25
-
-
79961005073
-
Class iii {beta}-Tubulin in advanced nsclc of adenocarcinoma subtype predicts superior outcome in a randomized trial
-
Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III {beta}-Tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17:5205-5214
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5205-5214
-
-
Vilmar, A.C.1
Santoni-Rugiu, E.2
Sorensen, J.B.3
-
26
-
-
34147187180
-
Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-Tubulins
-
Tommasi S, Mangia A, Lacalamita R et al (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-Tubulins. Int J Cancer 120:2078-2085
-
(2007)
Int J Cancer
, vol.120
, pp. 2078-2085
-
-
Tommasi, S.1
Mangia, A.2
Lacalamita, R.3
-
27
-
-
34247403761
-
Class iii beta-Tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
-
Seve P, Reiman T, Lai R et al (2007) Class III beta-Tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27-34
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 27-34
-
-
Seve, P.1
Reiman, T.2
Lai, R.3
-
28
-
-
84655170221
-
Low ercc1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival
-
Zimling ZG, Sorensen JB, Gerds TA et al (2012) Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 7:249-256
-
(2012)
J Thorac Oncol
, vol.7
, pp. 249-256
-
-
Zimling, Z.G.1
Sorensen, J.B.2
Gerds, T.A.3
-
29
-
-
46349111832
-
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
-
Sorensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99:44-50
-
(2008)
Br J Cancer
, vol.99
, pp. 44-50
-
-
Sorensen, J.B.1
Frank, H.2
Palshof, T.3
-
30
-
-
0029670327
-
A proposed new international tnm staging system for malignant pleural mesothelioma from the international mesothelioma interest group
-
Rusch VW (1996) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1-12
-
(1996)
Lung Cancer
, vol.14
, pp. 1-12
-
-
Rusch, V.W.1
-
31
-
-
1342267614
-
Modified recist criteria for assessment of response in malignant pleural mesothelioma
-
Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260
-
(2004)
Ann Oncol
, vol.15
, pp. 257-260
-
-
Byrne, M.J.1
Nowak, A.K.2
-
32
-
-
33746004548
-
Progression-free survival rate as primary end point for phase ii cancer clinical trials: Application to mesothelioma -The eortc lung cancer group
-
Francart J, Legrand C, Sylvester R et al (2006) Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma -The EORTC Lung Cancer Group. J Clin Oncol 24:3007-3012
-
(2006)
J Clin Oncol
, vol.24
, pp. 3007-3012
-
-
Francart, J.1
Legrand, C.2
Sylvester, R.3
-
33
-
-
0028113345
-
A strong candidate for the breast and ovarian cancer susceptibility gene brca1
-
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
-
(1994)
Science
, vol.266
, pp. 66-71
-
-
Miki, Y.1
Swensen, J.2
Shattuck-Eidens, D.3
-
34
-
-
0029115660
-
The developmental pattern of brca1 expression implies a role in differentiation of the breast and other tissues
-
Marquis ST, Rajan JV, Wynshaw-Boris A et al (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17-26
-
(1995)
Nat Genet
, vol.11
, pp. 17-26
-
-
Marquis, S.T.1
Rajan, J.V.2
Wynshaw-Boris, A.3
-
35
-
-
0033055801
-
Reduction of brca1 protein expression in japanese sporadic breast carcinomas and its frequent loss in brca1-Associated cases
-
Yoshikawa K, Honda K, Inamoto T et al (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-Associated cases. Clin Cancer Res 5:1249-1261
-
(1999)
Clin Cancer Res
, vol.5
, pp. 1249-1261
-
-
Yoshikawa, K.1
Honda, K.2
Inamoto, T.3
-
36
-
-
51049119252
-
Proteomic characterization of cytoskeletal and mitochondrial class iii beta-Tubulin
-
Cicchillitti L, Penci R, Di MM et al (2008) Proteomic characterization of cytoskeletal and mitochondrial class III beta-Tubulin. Mol Cancer Ther 7:2070-2079
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2070-2079
-
-
Cicchillitti, L.1
Penci R Di, M.M.2
-
37
-
-
77954321859
-
Metastatic non-smallcell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up
-
D'Addario G, Fruh M, Reck M et al (2010) Metastatic non-smallcell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116-v119
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
D'Addario, G.1
Fruh, M.2
Reck, M.3
-
38
-
-
34248378221
-
Expression of betatubulin isotypes in human primary ovarian carcinoma
-
Ohishi Y, Oda Y, Basaki Y et al (2007) Expression of betatubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105:586-592
-
(2007)
Gynecol Oncol
, vol.105
, pp. 586-592
-
-
Ohishi, Y.1
Oda, Y.2
Basaki, Y.3
-
39
-
-
84255206496
-
Cross-validation study of class iii beta-Tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials
-
Reiman T, Lai R, Veillard AS et al (2012) Cross-validation study of class III beta-Tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23:86-93
-
(2012)
Ann Oncol
, vol.23
, pp. 86-93
-
-
Reiman, T.1
Lai, R.2
Veillard, A.S.3
-
40
-
-
71049134390
-
Expression of ercc1 and class iiibeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer
-
Ikeda S, Takabe K, Suzuki K (2009) Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 59:863-867
-
(2009)
Pathol Int
, vol.59
, pp. 863-867
-
-
Ikeda, S.1
Takabe, K.2
Suzuki, K.3
-
41
-
-
67349275022
-
Expression of ercc1 and class iii beta-Tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
-
Azuma K, Sasada T, Kawahara A et al (2009) Expression of ERCC1 and class III beta-Tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326-333
-
(2009)
Lung Cancer
, vol.64
, pp. 326-333
-
-
Azuma, K.1
Sasada, T.2
Kawahara, A.3
-
42
-
-
0034548837
-
Phase ii study of vinorelbine in patients with malignant pleural mesothelioma
-
Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917
-
(2000)
J Clin Oncol
, vol.18
, pp. 3912-3917
-
-
Steele, J.P.1
Shamash, J.2
Evans, M.T.3
-
43
-
-
0036852721
-
Automated subcellular localization and quantification of protein expression in tissue microarrays
-
Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327
-
(2002)
Nat Med
, vol.8
, pp. 1323-1327
-
-
Camp, R.L.1
Chung, G.G.2
Rimm, D.L.3
-
44
-
-
69749092500
-
Standardization of her2 immunohistochemistry in breast cancer by automated quantitative analysis
-
Gustavson MD, Bourke-Martin B, Reilly D et al (2009) Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 133:1413-1419
-
(2009)
Arch Pathol Lab Med
, vol.133
, pp. 1413-1419
-
-
Gustavson, M.D.1
Bourke-Martin, B.2
Reilly, D.3
|